Last10K.com

Becton Dickinson Co (BDX) SEC Filing 10-Q Quarterly report for the period ending Tuesday, December 31, 2019

Becton Dickinson Co

HISTORY TOOLS
CIK: 10795 Ticker: BDX


Exhibit 99.1

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com



bda14.jpg



Contact:
Monique N. Dolecki, Investor Relations - 201-847-5378
Kristen Cardillo, Corporate Communications - 201-847-5657



BD ANNOUNCES RESULTS FOR 2020 FIRST FISCAL QUARTER;
LOWERS FISCAL 2020 GUIDANCE

•
As reported, revenues of $4.225 billion increased 1.6 percent.
•
On a currency-neutral basis, revenues increased 2.5 percent.
•
As reported, diluted earnings per share of $0.87 decreased 57.6 percent.
•
As adjusted, diluted earnings per share of $2.65 decreased 1.9 percent, or 0.4 percent on a currency-neutral basis.
•
The company is lowering its full fiscal year 2020 revenue and adjusted diluted earnings per share guidance to reflect the impact of the remediation effort and anticipated loss of sales of the Alaris infusion system.


Franklin Lakes, NJ (February 6, 2020) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.225 billion for the first fiscal quarter ended December 31, 2019. This represents an increase of 1.6 percent as reported over the prior-year period, or 2.5 percent on a currency-neutral basis.

BD also announced today that it is continuing to work with the U.S. Federal Drug Administration (FDA) on its software remediation plan for the Alaris System, which will require additional regulatory filings beyond what the company previously anticipated. The company expects to submit its comprehensive regulatory filing in the fourth quarter of fiscal year 2020. In the interim, the company will partner with the FDA and existing customers to ensure continued access to the Alaris System under medical necessity. As a result, the company is lowering its full fiscal year revenue and adjusted diluted earnings per share guidance.

“In the first quarter, the BD team delivered solid results, in line with our expectations,” said Tom Polen, CEO and president. “As we look ahead to the balance of the fiscal year, we are focused on the resolution of the Alaris pump matter. We stand behind the safety of the Alaris System, which is used in the care of 70 percent of patients undergoing infusion therapy. Now, we need to take the necessary steps to meet the FDA's expectations with respect to the Alaris System. We are committed to doing what is right for customers, patients and shareholders. You can expect that our purpose and values will always be at the core of who we are and how we work to resolve this situation moving forward.”



The following information was filed by Becton Dickinson Co (BDX) on Thursday, February 6, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Becton Dickinson Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Becton Dickinson Co.

Continue

Assess how Becton Dickinson Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Becton Dickinson Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Legal
Revenue
Other
Filter Subcategory:
All
Income
Expense
Geography
Product
Earnings
Shares
Cash Flow
Other
Inside Becton Dickinson Co's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover Page
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income
Condensed Consolidated Statements Of Income
Accounting Changes
Accounting Changes (Policies)
Basis Of Presentation
Benefit Plans
Benefit Plans (Tables)
Benefit Plans - Net Pension And Postretirement Cost (Detail)
Business Restructuring Charges
Business Restructuring Charges (Tables)
Business Restructuring Charges - Summary Of Restructuring Accrual Activity (Detail)
Contingencies
Contingencies - Additional Information (Detail)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (Tables)
Derivative Instruments And Hedging Activities - Additional Information (Detail)
Derivative Instruments And Hedging Activities Disclosure - Gains (Losses) On Net Investment Hedges (Details)
Divestiture
Divestiture - Additional Information (Details)
Earnings Per Share
Earnings Per Share (Tables)
Earnings Per Share - Weighted Average Common Shares Used In Computations Of Basic And Diluted Earnings Per Share (Detail)
Financial Instruments And Fair Value Measurements
Financial Instruments And Fair Value Measurements (Tables)
Financial Instruments And Fair Value Measurements - Additional Information (Detail)
Financial Instruments And Fair Value Measurements - Cash And Equivalents And Restricted Cash (Details)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Additional Information (Detail)
Intangible Assets - Components Of Intangible Assets (Detail)
Intangible Assets - Reconciliation Of Goodwill By Business Segment (Detail)
Leases
Leases (Tables)
Leases - Additional Information (Details)
Leases - Lessee, Operating Lease, Liability, Maturity (Details)
Leases - Schedule Of Future Minimum Rental Payments For Operating Leases (Details)
Leases - Supplemental Balance Sheet Information Related To Leases (Details)
Revenues
Revenues - Additional Information (Details)
Segment Data
Segment Data (Tables)
Segment Data - Additional Information (Detail)
Segment Data - Financial Information For Company's Segments (Detail)
Segment Data - Revenues By Geographic Areas (Detail)
Shareholders' Equity
Shareholders' Equity (Tables)
Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components And Changes Of Accumulated Other Comprehensive Income (Loss) (Detail)
Shareholders' Equity - Changes In Certain Components Of Shareholders' Equity (Details)
Subsequent Event (Details)
Subsequent Event (Notes)

Material Contracts, Statements, Certifications & more

Becton Dickinson Co provided additional information to their SEC Filing as exhibits

Exhibit 10.C: Material Contract
Exhibit 31: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32: Section 1350 Certification
Ticker: BDX
CIK: 10795
Form Type: 10-Q Quarterly Report
Accession Number: 0000010795-20-000010
Submitted to the SEC: Thu Feb 06 2020 4:00:19 PM EST
Accepted by the SEC: Thu Feb 06 2020
Period: Tuesday, December 31, 2019
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/bdx/0000010795-20-000010.htm